

Tuberculosis Detection, Revolutionized.


10.8 million people contracted TB in 2023, yet **over 2.5 million remained undiagnosed and untreated***, highlighting the critical diagnostics gap.

The active use of Chest X-Ray equipped with AI-Computer Aided Design as a screening solution in high TB burden countries can be a key to improving detection of even asymptomatic, subclinical TB, thereby linking the missing people to the care cascade.

With **ProDigi** - a patient registration platform, **ProRad Atlas** - an AI-powered, ultraportable, hand-held X-Ray, and **Truenat** - a real-time quantitative PCR platform, Molbio offers a comprehensive end-to-end solution for Tuberculosis response.

*Source : WHO Global TB Report 2024

Our End-to-End TB Screening and Testing Solution



ProDigi Platform



Capability to refer patient for E-Consultation

Our **Key** Products

ProDigi Health Platform

A cutting-edge, **AI-powered platform** enabling seamless patient registration, data capture, and report generation. Designed for flexibility, it operates in both cloud and on-premise modes, ensuring data integrity even in low-connectivity regions.



ProRad Atlas Ultraportable X-Ray

Lightweight, AI-enabled X-Ray system that **detects TB even in asymptomatic individuals.**

ProRad's digital platform uses artificial intelligence to analyze chest X-Rays, enabling early screening and detection of missing TB cases through high-resolution imaging within seconds.



Prognosys Medical Systems | a **molbio** company

Truenat Real Time PCR Platform

On-the-spot molecular testing that confirms TB with precision.

Truenat enables rapid point-of-care diagnosis, ensuring accurate results in under an hour and enabling immediate treatment initiation.



L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403 722, India



www.molbiodiagnostics.com